Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient

G. Varadi, A. Ackerstein, S. Ben-Neriah, A. Nagler

Research output: Contribution to journalArticlepeer-review

Abstract

A 21-year-old woman with chronic myelogenous leukemia (CML) relapsed into lymphoblastic crisis with new chromosomal translocations, 4 months following mismatched unrelated allogeneic bone marrow transplantation (BMT). Adoptive cell-mediated immunotherapy with mismatched unrelated donor lymphocytes followed by 3 days of in vivo interleukin-2 (IL-2) resulted in complete remission including disappearance of the Philadelphia chromosome as determined by cytogenetic analysis and the bcr/abl translocation detected by PCR. Lymphoblastic crisis following mismatched, unrelated BMT is relatively rare. Moreover lymphoblastic malignancies usually respond less favorably to cell-mediated immunotherapy. This case is the first reported CML lymphoblastic crisis following mismatched unrelated BMT that responded to cell-mediated immunotherapy and IL-2. Some possible mechanisms and new therapeutic directions are discussed.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalBone Marrow Transplantation
Volume21
Issue number1
DOIs
StatePublished - 1 Jan 1998
Externally publishedYes

Keywords

  • Allogeneic unrelated BMT
  • CML blastic crisis relapse
  • Donor leukocyte transfusion
  • Interleukin-2

Fingerprint

Dive into the research topics of 'Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient'. Together they form a unique fingerprint.

Cite this